Geron, Exeter Affiliates Merge to Create Livestock Cloning Shop
By GenomeWeb,
GenomeWeb
| 08. 12. 2008
NEW YORK (GenomeWeb News) - Geron and Exeter Life Sciences said today that Start Licensing, a joint venture between the two firms, and ViaGen, a subsidiary of Exeter, have merged to form a new entity that will focus on animal cloning.
Start manages and licenses a portfolio of intellectual property rights related to animal reproductive technologies, including nuclear transfer cloning technology that was developed at the Roslin Foundation to clone Dolly the sheep. ViaGen is an animal genomics and livestock cloning firm.
Geron and Exeter said that the merger of the firms combines the "full breadth" of Start's nuclear transfer cloning IP with ViaGen's in-house breeding services and expertise in advanced reproductive technologies, including cloning, "to provide a one-stop licensing and operating company" for animal cloning.
"We believe it makes sound business sense to join a patent estate for nuclear transfer that has been tested and is recognized as dominant with a leading operating company in the field," said David Greenwood, Geron's executive vice president and CFO, in a statement.
Jonathan Thatcher, Exeter Life Science's CEO, said that the combined...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...
